Chapter 10 Drug Therapy for Dyslipidemia - Call List

(Print) Use this randomly generated list as your call list when playing the game. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.

1. A-timeframe for maximum effect to begin for patients on Alirocumab
   A-1 week
2. H-carry lipids in blood by binding to specific proteins in plasma
   H-Lipoproteins
3. M-peak effect of fenofibrate
   M-6 to 8 hours
4. P-Therapeutic effect of fenofibrate is occur in approximately this timeframe
   P-1 month
5. P-what is the onset of therapeutic effects of statins
   P-1-2 weeks with maximum effect in 4-6 weeks
6. A-Primary prevention of cardiovascular risk factors associated with dyslipidemia
   A-Healthy Lifestyle
7. H-Contraindications of Ezetimibe
   H-Pregnancy Lactation Concomitant use with a statin in patients with active hepatic disease
8. A-Therapeutic response time of Ezetimibe
   A-2 weeks
9. H-myopathy, rhabdomyolysis, blood dyscrasias, hepatotoxicity, cholelithiasis, cholestatic jaundice, pancreatitis, and reduced libido
   H-Rare adverse effects of fenofibrate
10. G-Herbs shown to produce a decrease in LDL cholesterol
    G-Flaxseed Flaxseed ligans
11. G-Medications in the drug class Bile Acid Sequestrants
    G-Cholestyramine Colesevelam Colestipol
12. M-Which enzyme do the statins inhibit?
    M-HMG-CoA reductase
13. O-Is fenofibrate given with food or without food? It is necessary to give fenofibrate this way to increase drug absorption
    O-with food
14. M-Avoid taking statins with this liquid
    M-grapefruit juice
15. P-Ezetimibe is administered with what regard to food?
    P-with or without food
16. R-How should someone taking antacids take their prescribed statin?
    R-2 hours before or after antacids
17. O-observing and validating outcomes and interventions
    O-Evaluation
18. G-acts in the small intestine to inhibit absorption of cholesterol and decrease the delivery of intestinal cholesterol to the liver
    G-Action of Ezetimibe
19. H-Bile Acid Sequestrants
    H-may be used during pregnancy if needed to lower cholesterol
20. M-Adverse effects of Niacin
    M-increase blood sugar skin flushing pruritus GI irritation tachycardia hypotension dizziness
21. H-substances you can mix cholestyramine powder with
    H-Water, other fluids, soups, cereals, or fruits
22. O-binds bile acids int he intestinal lumen, causing the bile acids to be excreted in feces, preventing recirculation to the liver.
    O-Action of Cholestyramine
23. M-Medication belonging to the drug class Cholesterol Absorption Inhibitor
    M-Ezetimibe
24. P-A disorder of lipoprotein metabolism that causes abnormal lipid levels in the blood
    P-Dyslipidemia
25. O-Can patients with mild hepatic impairment take Ezetimibe?
    O-Yes, dosage adjustment is necessary
26. P-Main adverse effects are GI - abdominal fullness, flatulence, diarrhea, and constipation
    P-Adverse effect of Cholestyramine
27. A-True or False: It is ok for Cholestyramine to be taken in a dry form
    A-False
28. G-promote modulation of the receptor that clears cholesterol, thereby prolong the receptor activity and promoting the clearance of cholesterol
    G-Action of PCSK9 inhibitors
29. O-myopathies, myalgias, myositis, and muscle injury; more commonly - nausea, diarrhea, abdominal pain, dyspepsia, and elevated liver function tests
    O-adverse effects of statins
30. P-Statin with the highest rate of absorption
    P-Fluvastatin
31. H-Lab that is recommended before starting a statin, at 12 weeks after staring the drug, and at every increase in dose, then periodically.
    H-Liver function test
32. A-Drugs belonging to the drug class HMG-CoA Reductase Inhibitors
    A-Atorvastatin Fluvastatin Lovastatin Pravastatin Rosuvastatin
33. A-cholestyramine is not absorbed systemically and it may decrease absorption of many oral medications.
    A-True
34. M-Medications in the drug class PCSK9 Inhibitors
    M-Alirocumab Evolocumab
35. M-Determining patient's Risk factors, history, smoking history, and comorbidities are part of which nursing process?
    M-Assessment
36. G-increases the oxidation of fatty acids in liver and muscle tissue thus decreasing hepatic production of triglycerides, decrease VLDL cholesterol, and increase HDL cholesterol.
    G-Action of fenofibrate
37. A-Fenofibrate given with warfarin or other oral anticoagulants
    A-drug interaction increasing risk of bleeding
38. R-This medication demonstrates the most favorable benefit-cost ratio of the four commonly used statin drugs.
    R-Atorvastatin
39. R-a vitamin that is no longer recommended as a dyslipidemic agent except in patients with high triglyceride levels (greater than 500 m/dL)
    R-Niacin
40. O-adverse effect that the patient should notify health care provider for
    O-Patient develops cola-colored urine while on a statin
41. P-Adverse effects of Alirocumab
    P-Nasopharyngitis itching influenza muscle pain diarrhea serious allergic reactions
42. O-route of administration of Alirocumab
    O-Subcutaneous injection
43. G-Which medications are considered first-line therapy in the treatment of dyslipidemia in children?
    G-Statins
44. R-Adverse effects of Ezetimibe
    R-Headache Dizziness Fatigue Diarrhea Abdominal pain
45. H-subcutaneous injection sites
    H-upper arm abdomen thigh
46. R-Patient education for cholestyramine - Good oral hygiene needed because holding the mixture int he mouth can cause this...
    R-damages the teeth
47. G-Action statements such as helping patient control risk factors, requesting counseling/smoking cessations programs, administering medications per provider orders, educating patinet and family on disease processes,e tc.
    G-Nursing Interventions
48. R-Medications in the drug class Fibrates
    R-Fenofibrate Gemfibrozil